Disclosure, or open communication, by female microbicide trial participants of their trial participation and use of an investigational HIV prevention drug to a sexual partner may affect participants ’ trial product usage behavior and contribute to poor adherence. With mixed results from recent microbicide clinical trials being linked to differing participant adherence, insights into the communication dynamics between trial participants and their sexual partners are particularly important. We examined the quantitative association between (1) communication of trial participation to a partner and participant adherence to gel and (2) communication of trial participation to a partner and participant HIV status. An in-depth adherence and product ...
VOICE—a phase 2B, placebo-controlled, randomized trial testing daily use of an antiretroviral tablet...
FEM-PrEP did not demonstrate a reduction in HIV acquisition because of low study pill adherence. Yet...
Microbicides are a class of substances under development that could reduce the sexual transmission o...
BackgroundInterpretation of clinical trial results testing vaginal microbicide gels for HIV preventi...
Use of HIV prevention methods may vary for women by types of sexual partners. In a microbicide safet...
Low adherence in vaginal microbicide clinical trials for HIV prevention has impeded interpretation o...
Adherence undeniably impacts product effectiveness in microbicide trials, but the connection has pro...
The Author(s) 2014. This article is published with open access at Springerlink.com Abstract Adherenc...
The inconclusive results of past trials and recent findings of partial protection of Tenofovir 1% ge...
After two decades of microbicide clinical trials it remains uncertain if vaginally- delivered produc...
Background: Recently promising trials of innovative biomedical approaches to prevent HIV transmissio...
Background Recently promising trials of innovative biomedical approaches to prevent HIV transmission...
A randomized, placebo-controlled, efficacy trial of Carraguard was unable to demonstrate a reduction...
CAPRISA, 2014.High adherence is key to microbicide effectiveness. Here we provide a description of a...
Background: This research examined past microbicide effectiveness trials to better understand how ad...
VOICE—a phase 2B, placebo-controlled, randomized trial testing daily use of an antiretroviral tablet...
FEM-PrEP did not demonstrate a reduction in HIV acquisition because of low study pill adherence. Yet...
Microbicides are a class of substances under development that could reduce the sexual transmission o...
BackgroundInterpretation of clinical trial results testing vaginal microbicide gels for HIV preventi...
Use of HIV prevention methods may vary for women by types of sexual partners. In a microbicide safet...
Low adherence in vaginal microbicide clinical trials for HIV prevention has impeded interpretation o...
Adherence undeniably impacts product effectiveness in microbicide trials, but the connection has pro...
The Author(s) 2014. This article is published with open access at Springerlink.com Abstract Adherenc...
The inconclusive results of past trials and recent findings of partial protection of Tenofovir 1% ge...
After two decades of microbicide clinical trials it remains uncertain if vaginally- delivered produc...
Background: Recently promising trials of innovative biomedical approaches to prevent HIV transmissio...
Background Recently promising trials of innovative biomedical approaches to prevent HIV transmission...
A randomized, placebo-controlled, efficacy trial of Carraguard was unable to demonstrate a reduction...
CAPRISA, 2014.High adherence is key to microbicide effectiveness. Here we provide a description of a...
Background: This research examined past microbicide effectiveness trials to better understand how ad...
VOICE—a phase 2B, placebo-controlled, randomized trial testing daily use of an antiretroviral tablet...
FEM-PrEP did not demonstrate a reduction in HIV acquisition because of low study pill adherence. Yet...
Microbicides are a class of substances under development that could reduce the sexual transmission o...